Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (June 2026)
19 slides from Rhythm Biosciences's investor presentation, Jun 4, 2026
Slide 1: Rhythm Biosciences: An ASX Life Sciences Growth Opportunity
Rhythm Biosciences An ASX Life Sciences Growth Opportunity 4TH JUNE 2026 ASX: RHY
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Detecting cancer earlier to save lives
Detecting cancer earlier to save lives Rhythm Biosciences is an ASX listing company building precision diagnostics platform focused on earlier cancer detection, risk assessment and improve patient outcomes. Non-invasive blood-based bowel cancer detection test Assessing cancer risk before symptoms ap
Slide 4: Cancer is often detected too late
Cancer is often detected too late 15,500+ new colorectal cancer cases diagnosed every year in Australia >50% Diagnosed as late-stage disease – Stages III or IV 10% 5-year survival rate when diagnosed at Stage IV Earlier detection significantly improves survival outcomes and lowers treatment costs. R
Slide 5: Earlier diagnosis changes outcomes
Earlier diagnosis changes outcomes The need for cancer diagnostics is to move to earlier, simpler and more accessible disease detection. Diagnoses at Stage I or II only represent less than half of all CRCs diagnosed: Missed detection of early-stage CRC results in poor survival rates Stage I Stage II
Slide 6: Two complementary platforms. One precision cancer strategy.
Two complementary platforms. One precision cancer strategy. Rhythm is building a scalable precision diagnostics ecosystem across the cancer care pathway. Y N E R Risk Assessment Disease Screening U O J MONITORING AND Genomic cancer risk Blood-based cancer detection MINIMAL RESIDUAL T RISK ASSESSMENT
Slide 7: A blood-based colorectal cancer detection platform designed to aid effective early diagnosis
A blood-based colorectal cancer detection platform designed to aid effective early diagnosis. Rhythm Biosciences An ASX Life Sciences Growth Opportunity (ASX:RHY) www.rhythmbio.com
Slide 8: ColoSTAT®: Supporting Colorectal Cancer Triage
ColoSTAT®: Supporting Colorectal Cancer Triage Supporting colonoscopy decisions for symptomatic patients underserved by traditional methods Global Triage Opportunity 22M annual tests1 Avoidance of existing screens +ROW: 1.6m Many patients avoid or decline traditional +ASPAC: 2.7m stool-based screeni
Slide 9: Scaling ColoSTAT® Commercial Adoption
Scaling ColoSTAT® Commercial Adoption Clinically validated. Partner-enabled. Commercially scalable. Target Market Commercial Channels Commercial Validation Accessible, non-invasive cancer detection National healthcare engagement pathway Supporting physician confidence • Patients underserved by Prima
Slide 10: Personalised cancer risk assessment designed to support earlier detection and prevention
Personalised cancer risk assessment designed to support earlier detection and prevention. Rhythm Biosciences An ASX Life Sciences Growth Opportunity (ASX:RHY) www.rhythmbio.com
Slide 11: Predicting cancer risk before symptoms appear
Predicting cancer risk before symptoms appear Clinically validated precision cancer risk assessment platform Combines genomic and Validated across six cancer indications with data from 100,000s of clinical data to support individuals personalised prevention and screening Personalised using genomic a
Slide 12: Personalised cancer risk assessment at scale
Personalised cancer risk assessment at scale Predicting cancer risk before symptoms appear RISK RISK TAILORED Genetype Clinical Applications ASSESSMENT STRATIFICATION SCREENING • Individualised patient care • Institutional/payor Intensified screening, Medication, surgery • Primary care level care •
Slide 13: Scaling Commercial Adoption
Scaling Commercial Adoption Genetype Target Segments Oncology Channel Portfolio Focus Strategy • Health Care • Breast* Professionals – B2B Volume from enterprise accounts & • Prostate • Strategic partners/ Enterprise accounts - strategic partners • Colorectal* B2B2C • Ovarian Competition • Melanoma
Slide 14: Commercial-stage cancer diagnostics platforms entering a significant growth phase
Commercial-stage cancer diagnostics platforms entering a significant growth phase. Rhythm Biosciences An ASX Life Sciences Growth Opportunity (ASX:RHY) www.rhythmbio.com
Slide 15: Why Rhythm, Why Now?
Why Rhythm, Why Now? Dual-platform precision diagnostics strategy • Combining earlier cancer detection and personalised risk assessment Commercialisation underway • Commercial validation, partnerships and rollout progressing across several markets Large addressable markets • Exposure to growing glob
Slide 16: Rhythm at a glance
Rhythm at a glance Building a scalable precision diagnostics platform Corporate Snapshot 3rd June 2026 ASX Code RHY RISK ASSESSMENT geneType Share Price $0.115 Personalised cancer risk assessment designed to support earlier detection and Shares on Issue 353.9M prevention. Unlisted & Listed Options 7
Slide 17: Near-Term Growth Catalysts
Near-Term Growth Catalysts Positioned for the next phase of commercial expansion and international growth. PRODUCT MILESTONE DESCRIPTION COMPLETION DATE ColoSTAT® Scaling commercial footprint Activation of 4Cyte collection centres Q4 FY2026 geneType strategic Establishment of key international and d
Slide 18: Team
Team Experienced diagnostics leadership executing the next phase of commercial growth Jackson Jones Nir Dvorski Chief Commercial Officer Chief Operations Officer David Atkins, PhD Sue MacLeman Gavin Fox-Smith CEO & MD Non-Executive Director Non-Executive Chairman Former CEO of Congenica (UK) & 30 ye
Slide 19: Thank you!
Thank you! David Atkins, PhD CEO & MD david.atkins@rhythmbio.com www.rhythmbio.com Rhythm Biosciences An ASX Life Sciences Growth Opportunity (ASX:RHY)
Rhythm Biosciences — Investor Presentation (June 2026) on 6ix